Yes, there is a semaglutide pill — here's what the evidence says

How the OASIS 4 trial established the pill's effectiveness

The MHRA's approval of Wegovy tablets rested primarily on the OASIS 4 phase-3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, followed for 64 weeks alongside lifestyle changes. The headline result was a mean weight loss of around 13.6% in the semaglutide group versus roughly 2.4% with placebo — a clinically meaningful difference, and one that holds up even when accounting for participants who did not take every dose. Among those who stayed fully adherent throughout the study, average weight loss reached around 16.6%. That higher figure is real, but it reflects the most consistent users, not the trial average; responsible reporting keeps both numbers in view.

Gastrointestinal effects were the most commonly reported side effects, occurring in 74% of participants on the tablet compared with 42% on placebo. These were generally mild to moderate and tended to settle over time, the same pattern seen with the injectable form. You can find the full prescribing detail in the Wegovy tablets Summary of Product Characteristics on the electronic Medicines Compendium (eMC).

One question our prescribers hear regularly: does the pill work as well as the injection? The honest answer is that the 13.6% average sits below the roughly 15% seen with semaglutide 2.4 mg weekly in the STEP 1 trial, and if you have been wondering whether there is a pill version of Wegovy and how it compares, the answer is yes, though oral bioavailability of semaglutide is lower than subcutaneous delivery, which is why the maintenance tablet dose reaches 25 mg, a much larger number than the 2.4 mg injection dose, though the two are not directly comparable by number.

What taking the pill actually involves

The dosing schedule starts at 1.5 mg daily and steps up through 4 mg and 9 mg before reaching the 25 mg maintenance dose, with at least one month at each level. The titration exists for the same reason the injection's escalation does: letting your system adjust reduces the intensity of early nausea.

How it is taken matters more than with most medicines. The tablet must be swallowed whole, first thing in the morning, on a completely empty stomach, with a small amount of plain water, up to around 120 ml. Nothing else. No coffee, no other tablets, no breakfast for at least 30 minutes afterwards. The SNAC absorption-enhancer in the formulation relies on the stomach's acidity being undiluted; food or other drinks interfere with uptake. Think of it as the first thing you do before the kettle even goes on.

Storage is notably simpler than the injection. Room temperature is fine, no fridge, no cold chain, no worrying about a hotel minibar. For anyone who travels frequently or simply finds injectable medicines daunting, that practical difference matters. For more on how the tablet compares to the injection, the full comparison of Wegovy pill and injection options covers the two side by side.

Who the semaglutide pill is licensed for, and what it is not

The MHRA licensed Wegovy tablets for adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. That matches the injection's eligibility in broad terms, though a prescriber assesses the full picture, BMI alone is never the only consideration. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance.

Two distinctions are worth being clear about. First, if you are researching what the semaglutide pill is and how it works, it is important to know that Rybelsus is also an oral semaglutide tablet, but at doses of 3 mg, 7 mg and 14 mg it is licensed for type 2 diabetes, not weight management, those strengths are entirely separate from the Wegovy tablet schedule. Second, Wegovy tablets are not yet available on the NHS; a NICE appraisal would be required before NHS commissioning could begin, so for now this is a private prescription medicine. The guide to obtaining semaglutide tablets in the UK explains the private route, what to look for in a legitimate provider, and how to verify any online pharmacy on the GPhC register.

For anyone considering the tablet alongside other medicines (including oral contraceptives) a conversation with a prescriber is essential before starting. As noted in NHS England's guidance on weight-management injections, the broader semaglutide class can affect absorption of other oral medicines depending on the timing and formulation involved; your prescriber will factor that in.

What this means if you are considering a tablet-based option

The existence of a licensed oral semaglutide option genuinely widens the choice available to adults seeking prescription weight-management treatment in the UK. Some people have a real aversion to weekly injections. Others need room-temperature storage. For them, the tablet form removes a barrier that the injection never could.

That said, many people ask whether there is a Wegovy pill and whether it is right for them, and the honest answer is that the pill is not automatically the better option. The injection's evidence base is larger, its maintenance dose produces somewhat higher average weight loss in trial data, and it requires less precise timing. The right choice depends on your health history, other medicines you take, your daily routine, and a frank conversation with a prescriber who knows your situation. You can read more about the full range of licensed weight-loss treatment options or, if you are ready to discuss which approach suits you, our clinical team at nume (sorry, at our clinical team page) reviews every consultation personally. When you are ready to take the next step, start your free consultation and a GPhC-registered prescriber will review your answers the same day.